Short Interest in Aclarion, Inc. (NASDAQ:ACON) Decreases By 11.2%

Aclarion, Inc. (NASDAQ:ACON) was the target of a large drop in short interest during the month of November. As of November 15th, there was short interest totalling 380,900 shares, a drop of 11.2% from the October 31st total of 428,800 shares. Approximately 3.8% of the company’s shares are sold short. Based on an average daily trading volume, of 480,800 shares, the days-to-cover ratio is currently 0.8 days.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets lowered their target price on Aclarion from $1.50 to $1.30 and set a “buy” rating for the company in a research report on Wednesday, November 27th.

Aclarion Trading Up 1.6 %

Shares of ACON stock opened at $0.18 on Monday. Aclarion has a fifty-two week low of $0.16 and a fifty-two week high of $7.40. The stock has a 50 day simple moving average of $0.18 and a two-hundred day simple moving average of $0.24.

Institutional Trading of Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC purchased a new position in Aclarion, Inc. (NASDAQ:ACON) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned 1.40% of Aclarion at the end of the most recent quarter. Institutional investors own 7.52% of the company’s stock.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.